Modular Medical Gains FDA 510(k) Clearance for Pivot Pump Targeting $3B Market
Modular Medical secured FDA 510(k) clearance for its Pivot two-part tubeless patch pump, unlocking U.S. commercial sales and targeting the $3 billion "almost-pumper" market. Manufacturing validation lots support initial capacity for 6,000 users and shipments are slated by end of Q2 2026, with CE Mark planned by early 2027.
1. FDA Clearance Unlocks Commercial Sales
Modular Medical received FDA 510(k) clearance for its Pivot two-part tubeless insulin patch pump, enabling U.S. commercial sale. This regulatory milestone removes a key barrier, de-risking revenue prospects and positioning the company for market entry.
2. Pivot Pump Design and Features
The Pivot system features a removable 3 mL reservoir with disposable battery, smartphone-controlled bolus delivery and true electronic accuracy without tubes. Its two-part design allows users to detach the pump for activities like showering and sports, enhancing convenience and discretion.
3. Market Opportunity and Adoption
Pivot addresses the estimated $3 billion 'almost-pumper' segment, where 70% of insulin-dependent adults remain on multiple daily injections. By simplifying pump therapy and reducing costs, the company aims to convert millions of injection users to its platform and capture significant market share.
4. Manufacturing and Commercial Timeline
Production validation lots are underway, supporting initial capacity for approximately 6,000 users. Initial customer shipments are scheduled by end of Q2 2026, and a CE Mark application is targeted for Q4 2026 to Q1 2027 to expand into European markets.